EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells

Ramy Ashry iD, Mohamed Abdelsalam iD, Julia Hausen, Christoph Hieber iD, Yanira Zeyn iD, Anne-Christin Sarnow iD, Matthias Schmidt iD, Sara Najafi, Ina Oehme, Matthias Bros iD, Jia-Xuan Chen iD, Mario Dejung iD und 2 weitere

Angewandte Chemie International Edition · 01.12.2025 · 64 (49)

DOI: 10.1002/anie.202514788 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 17.10.2025. Verfasst von Ramy Ashry und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology, University Medical Center, 55131, Mainz, Germany. Hauptthemen laut MEDLINE: Checkpoint Kinase 1, Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation/Deutsche Forschungsgemeinschaft (DFG), Deutsche Forschungsgemeinschaft, Walter Schulz-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint kinase‐1 (CHK1) controls DNA replication and repair. Tumor cells depend on CHK1, whose high levels are associated with worse patient prognosis. We define a bona fide proteolysis‐targeting‐chimera (PROTAC) for CHK1. PROTAC MA203 contains the type I kinase inhibitor rabusertib, which preferentially inhibits activated CHK1, and the cereblon (CRBN) ligand pomalidomide. MA203 accelerates CRBN‐dependent proteasomal degradation of CHK1 in solid tumor‐derived cells and acute leukemia cells. Chemotherapy‐induced DNA replication stress and a consequent activation of CHK1 accelerate this event‐driven process which promotes DNA damage and tumor cell apoptosis. Biochemical and cellular target engagement studies confirm the potency and selectivity of MA203. MA203 does not damage healthy differentiated and primitive hematopoietic cells, stromal cells, and retinal epithelial cells. MA203 is superior to its corresponding kinase inhibitor concerning DNA damage, dysregulation of BCL2 proteins, and apoptosis induction. These processes occur independently of the tumor‐suppressive transcription factor p53. Elimination of CHK1 protein as structural element, but not its inhibition per se, triggers a proteasomal degradation of key DNA replication and repair proteins. Genetic CHK1 elimination confirms that such newly recognized functions of CHK1 rely on functions beyond its well‐known catalytic activity. Thus, kinase‐independent functions of CHK1 can be exploited with innovative pharmacological agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Checkpoint Kinase 1Protein Kinase InhibitorsNeoplasmsAntineoplastic AgentsHumansProteolysisApoptosisCell Line, TumorDNA Damage

Stichwörter der Autor:innen

CHK1Cancer cellsCereblonDNA replication stressPROTAC

Substanzen

Checkpoint Kinase 1CHEK1 protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Toxicology, University Medical Center, 55131, Mainz, Germany.
  • Department of Oral Pathology, Faculty of Dentistry, Mansoura University, Mansoura, 35516, Egypt.
  • Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120, Halle (Saale), Germany.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
  • Department of Dermatology, University Medical Center, 55131, Mainz, Germany.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.

ORCID-Profile: Ramy Ashry, Mohamed Abdelsalam, Christoph Hieber, Yanira Zeyn, Anne-Christin Sarnow, Matthias Schmidt, Matthias Bros, Jia-Xuan Chen, Mario Dejung, Wolfgang Sippl, Oliver H Krämer

Förderung

  • German Research Foundation/Deutsche Forschungsgemeinschaft (DFG)
  • Deutsche Forschungsgemeinschaft
  • Walter Schulz-Stiftung
  • José Carreras Leukemia Foundation
  • H.W. & J. Hector Stiftung
  • Brigitte und Dr. Konstanze Wegener-Stiftung
  • Alexander von Humboldt Foundation
  • DAAD Egypt/Germany

Zitieren

APA

Ashry, R., Abdelsalam, M., Hausen, J., Hieber, C., Zeyn, Y., Sarnow, A. C., Schmidt, M., Najafi, S., Oehme, I., Bros, M., Chen, J. X., Dejung, M., Sippl, W., & Krämer, O. H. (2025). Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells. Angewandte Chemie International Edition, 64(49). https://doi.org/10.1002/anie.202514788

Vancouver

Ashry R, Abdelsalam M, Hausen J, Hieber C, Zeyn Y, Sarnow AC, et al. Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells. Angewandte Chemie International Edition. 2025;64(49). doi:10.1002/anie.202514788

BibTeX
@article{Ashry2025,
  author = {Ashry, Ramy and Abdelsalam, Mohamed and Hausen, Julia and Hieber, Christoph and Zeyn, Yanira and Sarnow, Anne-Christin and Schmidt, Matthias and Najafi, Sara and Oehme, Ina and Bros, Matthias and Chen, Jia-Xuan and Dejung, Mario and Sippl, Wolfgang and Krämer, Oliver H},
  title = {Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  volume = {64},
  number = {49},
  doi = {10.1002/anie.202514788}
}
Kostenlos starten →